UROV Urovant Sciences Ltd.

9.56
+0.41  (+4%)
Previous Close 9.15
Open 9.57
Price To Book 3.87
Market Cap 289,958,930
Shares 30,330,432
Volume 10,921
Short Ratio
Av. Daily Volume 61,636

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial to be initiated 4Q 2019.
hMaxi-K
Overactive bladder (OAB)
Phase 2 top-line data due 2020.
Vibegron
Irritable bowel syndrome (IBS)
Phase 3 trial initiation announced March 27, 2019. Completion of Part 1 due 2H 2019.
Vibegron - COURAGE
Overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH)
Phase 3 data released March 18, 2019 - primary endpoints met.
Vibegron
Overactive bladder (OAB)

Latest News

  1. Here’s What Hedge Funds Think About Urovant Sciences Ltd. (UROV)
  2. Urovant Sciences Ltd. (NASDAQ:UROV): Immense Growth Potential?
  3. Urovant Sciences Reports Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
  4. Urovant Sciences Ltd. to Host Earnings Call
  5. Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
  6. Urovant Sciences to Present at Annual Roivant Pipeline Day
  7. Urovant Sciences to Present at the Jefferies 2019 Healthcare Conference
  8. Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting
  9. Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting
  10. Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
  11. Here's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data
  12. Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
  13. Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
  14. Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
  15. Urovant Sciences Appoints James Robinson to its Board of Directors
  16. Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript
  17. Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
  18. Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
  19. Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
  20. Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019